Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.53 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | P4HB | P07237 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484363 | 1.00 | F3 (0.54) | F3KMT2ACYP3A4HSPD1HSPE1 | |
| SCHEMBL30383944 | 1.00 | F3 (0.54) | F3KMT2ACYP3A4HSPD1HSPE1 | |
| SCHEMBL3484322 | 0.88 | MAPT (0.52) | KMT2AMAPTMEN1P4HBCXCL12 | |
| SCHEMBL30383490 | 0.88 | MAPT (0.52) | KMT2AMAPTMEN1P4HBCXCL12 | |
| SCHEMBL3484320 | 0.88 | MAPT (0.52) | KMT2AMAPTMEN1P4HBCXCL12 | |
| SCHEMBL25195314 | 0.86 | MAOB (0.54) | F3KMT2ACYP3A4HSPD1HSPE1 | |
| SCHEMBL3484447 | 0.86 | F3 (0.54) | F3KMT2ACYP3A4HSPD1HSPE1 | |
| SCHEMBL25197330 | 0.86 | ESR1 (0.54) | F3KMT2ACYP3A4HSPD1HSPE1 | |
| SCHEMBL25190825 | 0.86 | MAPT (0.54) | F3KMT2ACYP3A4HSPD1HSPE1 | |
| SCHEMBL30384281 | 0.86 | F3 (0.54) | F3KMT2ACYP3A4HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601943-B1 | Anti-cancer composition containing chalcone compounds | SEOUL NAT UNIV IND FOUNDATION (KR) | 2015-07-22 | — | — | EP | claimed |
| US-20130178533-A1 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE | SNU R&DB FOUNDATION (KR) | 2013-07-11 | — | — | US | claimed |
| EP-2601943-A1 | Anti-cancer composition containing chalcone compounds | Seoul National University Industry Foundation (KR) | 2013-06-12 | — | — | EP | claimed |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-03-18 | — | — | US | claimed |
| EP-2099440-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | Seoul National University Industry Foundation (KR) | 2009-09-16 | — | — | EP | claimed |
| WO-2008069608-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-06-12 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-2601943-B1 | Anti-cancer composition containing chalcone compounds | SEOUL NAT UNIV IND FOUNDATION (KR) | 2015-07-22 | — | — | EP | disclosed |
| US-9072698-B2 | Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2015-07-07 | — | — | US | disclosed |
| US-9057725-B2 | Composition for diagnosing, treating, and preventing liver disease | SNU R&DB FOUNDATION (KR) | 2015-06-16 | — | — | US | disclosed |
| US-20130178533-A1 | COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE | SNU R&DB FOUNDATION (KR) | 2013-07-11 | — | — | US | disclosed |
| EP-2601943-A1 | Anti-cancer composition containing chalcone compounds | Seoul National University Industry Foundation (KR) | 2013-06-12 | — | — | EP | disclosed |
| US-8445722-B2 | Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) | 2013-05-21 | — | — | US | disclosed |
| EP-2099440-B1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 | SEOUL NAT UNIV IND FOUNDATION (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120282619-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY | 2012-11-08 | — | — | US | disclosed |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | F3 5/4885KMT2A 2792/4885CYP3A4 928/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | F3 11/4885KMT2A 3188/4885CYP3A4 1589/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | F3 11/4885KMT2A 3188/4885CYP3A4 1589/4885 |
| US-20100068730-A1 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS | TM9SF4, TM9SF2, TM9SF3 | F3 170/4885KMT2A 3351/4885CYP3A4 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.